Moreover, administration of IL-33 during the recovery phase of DSS-induced colitis in mice was shown to enhance recovery, by skewing the accumulation of TH2 and TREG cells over TH1/TH17 responses in the gut (160). This evidence concerns the gene IL33 and colitis.